Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00273273 · ClinicalTrials.gov registry record
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 30
- Enrollment target
NCT00273273: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT00273273 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00273273 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this project is to study the pharmacokinetics of a once-daily antiretroviral medication used to treat adolescents and young adults with HIV infection.
Primary Outcome
To measure the pharmacokinetics of atazanavir/ritonavir and tenofovir when used in combination to treat HIV-infected adolescents and young adult subjects
Interventions
- PROCEDURE blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-12 |
What the finished NCT00273273 record still lists
NCT00273273 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which blood draw is the first listed.
NCT00273273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00273273 about?
NCT00273273 is a clinical study titled "PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir". The purpose of this project is to study the pharmacokinetics of a once-daily antiretroviral medication used to treat adolescents and young adults with HIV infection.
What is the current status of trial NCT00273273?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2006-02. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00273273?
The interventions under investigation include: blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT00273273?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia